8/12/2022
RedChip Logo

RedChip Companies

Weekly Newsletter
 

TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology

Before the COVID-19 pandemic, most people only knew what mRNA is if they remembered their high school biology classes and actually studied for the exams.

Those folks may remember mRNA stands for Messenger RNA. It tells your DNA how to make specific proteins. The mRNA contains instructions that your body can read to create a special type of protein. This protein triggers your immune system, which then creates antibodies specific to COVID-19 or any other disease being thwarted by mRNA vaccines.

But today, after more than 10 billion people have been injected with mRNA vaccines for COVID, consumers and scientists alike have been wondering what’s next for the science of mRNA.

Scientists at Transcode Therapeuitics, Inc. (NASDAQ: RNAZ) have a message for those wondering: This is what’s next.

TransCode Therapeutics, the RNA oncology company committed to defeating cancer using RNA therapeutics, and  The University of Texas MD Anderson Cancer Center recently announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

Through the alliance, TransCode and MD Anderson scientists will collaborate on preclinical studies to further validate TransCode’s therapeutic and diagnostic candidates and to expand the reach of TransCode’s discovery engine. The results of these studies will inform future clinical trials with these agents, including trials to be led at MD Anderson.

“RNA-based therapeutics offer exciting possibilities to treat cancer. We can now examine how regulatory RNAs affect signaling, both spatially and temporally, at the single-cell level in tumor cells, immune cells and stem cells — all critical for tumor progression, relapse and immune evasion,” said principal investigator Sendurai Mani, Ph.D., Professor of Translational Molecular Pathology. “Our goals in collaborating with TransCode are to gain a deeper understanding of RNA-targeted therapies and to bring innovative new treatment options to our patients.”

The collaboration has the potential to inform multiple clinical programs in TransCode’s pipeline, starting with its lead therapeutic candidate, TTX-MC138, designed to treat multiple metastatic cancers. Future clinical trials will be designed and led by Vivek Subbiah, M.D., Associate Professor of Investigational Cancer Therapeutics at MD Anderson.

“This strategic alliance offers the opportunity to further unlock the potential of our therapeutic pipeline by combining the promise of our image capable delivery platform and discovery engine with the unique talent and resources found at MD Anderson,” said Zdravka Medarova, PhD, Co-Founder and CTO of TransCode.

For more information, visit www.transcodetherapeutics.com

 
See More Info
 
 
 

1847 Holdings LLC Announces Closing of $6 Million Public Offering of Common Shares

1847 Holdings LLC (NYSE American:EFSH), a publicly traded holding company platform that combines the attractive attributes of private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced the closing of its underwritten public offering of 1,428,572 Common Shares at a public offering price of $4.20 per share. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by 1847 Holdings, was $6 million. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 214,286 Common Shares (equal to 15% of the Common Shares sold in the offering), at the public offering price less the underwriting discounts and commissions, to cover over-allotments, if any.


 
Learn More
   

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced the following:

  • As previously disclosed, clinical trial contracts and budgets have been executed at multiple hospitals and the largest oncology network in the US. Clinical site initiation visits to train clinicians, nurses, coordinators, and pharmacists are underway, after which sites will be activated and the Flamingo-01 Phase III clinical trial will commence.
  • The Company is continuing to make progress to initiate clinical sites in Europe through oncology networks, potentially including networks in Germany, Spain, and France.
 
Learn More
 

EV Technology Group’s Strategic Partner, MOKE International, Launches ‘Casa MOKE’ Flagship Store in Saint-Tropez and Unveils New Website, Integrating an End-to-End MOKE Customer Experience

EV Technology Group Ltd.(NEO: EVTG, OTCQB: EVTGF, DE: B96A) announced that its strategic partner MOKE International Limited, working with its distribution partner MOKE France SAS, has opened the doors of its new flagship store in its spiritual home, Saint-Tropez, France. Additionally, it has launched a brand-new website offering the unique MOKE experience online, where potential owners across the UK and Europe can configure their Electric MOKE and pay GBP£990 to secure their pre-orders and join the waiting list.

The new website gives customers the freedom to decide between having a new Electric MOKE delivered to a convenient address of their choice, or to collect it in person at Casa MOKE, situated in one of the world’s most glamourous locales.

 
Learn More
 

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for its patent application, CA 2937649, entitled "Abuse and Misuse Deterrent Transdermal Systems," that protects its AVERSA™ transdermal abuse deterrent technology.  Nutriband's AVERSA™ abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential such as opioids used to treat moderate to severe chronic pain, while making sure that these drugs remain accessible to those patients who really need them.

 
Learn More
 

 
 

Upcoming Events

16
August
2022
NASDAQ: GLSI - Greenwich LifeSciences
4:15pm Eastern
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and is planning to commence a Phase III clinical trial.
 
Sign Up
 
17
August
2022
OTC: EMOR - Healixa, Inc.
11:00am Eastern
Healixa is a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water generation and green-tech industries.
 
Sign Up
 
17
August
2022
NASDAQ: SPRC - SciSparc Ltd.
4:15pm Eastern
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders.
 
Sign Up
 
18
August
2022
NASDAQ: SYTA - Siyata Mobile
11:00am Eastern
Siyata Mobile (Siyata or the Company) is a leading developer and distributor of technologically advanced rugged smartphones, in-vehicle mounted IoT cellular communications devices, and cellular signal boosters for global first responders and enterprise customers based on Push-to-Talk Over Cellular (PoC) technology.
 
Sign Up
 
18
August
2022
NASDAQ: APM - Aptorum Group
4:15pm Eastern
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapeutic assets to treat diseases with unmet medical needs.
 
Sign Up
 
18
August
2022
NASDAQ: RVPH - Reviva Pharmaceutical
4:15pm Eastern
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families.
 
Sign Up
 
 
 

Archive Events

9
August
2022
NASDAQ: IINN - Inspira Technologies
Meeting Duration 32 minutes
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure.
 
Watch Replay
 
4
August
2022
OTCQB: EVTGF - EV Technology Group
Meeting Duration 38 minutes
EV Technology Group was founded in 2021 with the vision to electrify iconic brands – and the mission to redefine the joy of motoring for the electric age.
 
Watch Replay
 
3
August
2022
OTCQB: CVAT - Cavitation Technologies
Meeting Duration 41 minutes
Cavitation Technologies, Inc. (CTi) is an innovative leader in processing liquids, fluidic mixtures, emulsions and suspended solids. The Company focuses on the practical implementation of in-house innovations and breakthroughs and sees its main mission as addressing the current and future needs of major industries.
 
Watch Replay
 
1
August
2022
NASDAQ: GENE - Genetic Technologies Limited
Meeting Duration 45 minutes
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health.
 
Watch Replay
 
 
 

Lesson of the Week

Most fund managers don't generate enough returns to cover their expenses.

 
Learn More
 
 
 
All Videos
Full Episodes
 

RedChip TV

This Week on RedChip TV: 2 Small-Cap EV Stocks with Potential to Dominate

Save Foods: Extending the Shelf Life of Fresh Produce with Innovative Technology

Aptorum Group (Nasdaq: APM): Innovations for Infectious Diseases, Oncology, and Women’s Health

BTCS Inc. (NASDAQ: BTCS): Advancing Blockchain Protocols and Data

Sharps Technology: Protection by Design with This Groundbreaking Product

Medalist REIT: Opportunistic Investing Strategy with Diversified Property Portfolio

 
 

MidSouth Week in Review

Wholesale gas prices declined to $2.75 vs. $4.33 in June and have declined 50 straight days.

 
Learn More
 
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
© 2022 RedChip , All rights reserved